Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Guillem Jorba"'
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract Druggable pockets are protein regions that have the ability to bind organic small molecules, and their characterization is essential in target-based drug discovery. However, deriving pocket descriptors is challenging and existing strategies
Externí odkaz:
https://doaj.org/article/8c11db43ff354f759520de8c28ea0279
Autor:
Pablo Coto-Segura, Cristina Segú-Vergés, Antonio Martorell, David Moreno-Ramírez, Guillem Jorba, Valentin Junet, Filippo Guerri, Xavier Daura, Baldomero Oliva, Carlos Cara, Olaya Suárez-Magdalena, Sonya Abraham, José Manuel Mas
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundPsoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes. Certolizumab pegol [CZP], a
Externí odkaz:
https://doaj.org/article/9303c230818e4c188b68993bece78e06
Autor:
José Ramón Gutiérrez-Casares, Javier Quintero, Guillem Jorba, Valentin Junet, Vicente Martínez, Tamara Pozo-Rubio, Baldomero Oliva, Xavier Daura, José Manuel Mas, Carmen Montoto
Publikováno v:
Frontiers in Psychiatry, Vol 12 (2021)
Regulatory agencies encourage computer modeling and simulation to reduce the time and cost of clinical trials. Although still not classified in formal guidelines, system biology-based models represent a powerful tool for generating hypotheses with gr
Externí odkaz:
https://doaj.org/article/a6bb124783584afe9bbbde6500ed2a42
Autor:
Guillem Jorba, Joaquim Aguirre-Plans, Valentin Junet, Cristina Segú-Vergés, José Luis Ruiz, Albert Pujol, Narcís Fernández-Fuentes, José Manuel Mas, Baldo Oliva
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0228926 (2020)
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of diff
Externí odkaz:
https://doaj.org/article/b6a9cf8a9bc0471c821aed9b45a5eda8
Autor:
Pedro Matos-Filipe, Juan Manuel García-Illarramendi, Guillem Jorba, Baldo Oliva, Judith Farrés, José Manuel Mas
IntroductionRandomized clinical trials (RCT) are limited in reflecting observable results out of controlled settings, which requires the execution of further lengthy observational studies. The usage of real-world data (RWD) has been recently consider
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4c83d986823550315a277a992afbe93
https://doi.org/10.1101/2022.11.10.515995
https://doi.org/10.1101/2022.11.10.515995
Autor:
Vladimir Kirkin, Ole Pless, Judith Farres, Saba Ezazi Erdi, Muhammed Kocak, Ana Martínez, Inés Maestro, Guillem Jorba
Publikováno v:
Digital.CSIC: Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Autophagy
Digital.CSIC. Repositorio Institucional del CSIC
instname
Consejo Superior de Investigaciones Científicas (CSIC)
Autophagy
Digital.CSIC. Repositorio Institucional del CSIC
instname
Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has
Autor:
José Manuel Mas, Carmen Montoto, Andrea Naves, Baldomero Oliva, Alonso Fernández-Nistal, Araceli López, Cristina Segú-Vergés, Enric Carcereny, Guillem Jorba, Mireia Coma
Publikováno v:
Oncotarget
Around 3–7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling pathway. The developed ALK tyr
Autor:
José Manuel Mas, José Luis Ruiz, Valentin Junet, Narcis Fernandez-Fuentes, Guillem Jorba, Cristina Segú-Vergés, Baldo Oliva, Joaquim Aguirre-Plans, Albert Pujol
Publikováno v:
PLoS ONE
PLOS ONE
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
PLoS ONE, Vol 15, Iss 2, p e0228926 (2020)
PLOS ONE
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
PLoS ONE, Vol 15, Iss 2, p e0228926 (2020)
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of diff
Autor:
Valentin Junet, Guillem Jorba, Cristina Segú-Vergés, Joaquim Aguirre-Plans, Albert Pujol, José Manuel Mas, Narcis Fernandez-Fuentes, José Luis Ruiz, Baldo Oliva
Publikováno v:
bioRxiv
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of drug(s) in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55eda2c155eb89bc676a27be026d7bc5
https://doi.org/10.1101/625889
https://doi.org/10.1101/625889